This news article summarizes an evaluation of longer-term quality of life at the 18-month mark among patients with lymph node–positive or high-risk lymph node–negative breast cancer who had completed active treatment in the phase III trial E5103. The analysis, led by Shoshana M. Rosenberg, ScD, MPH (Dana-Farber Cancer Institute), was recently published in JAMA Network Open (February 2022).